Kornimate/medical-research-clean huggingface dataset:
assessing contacts' decision making on reducing the risk of pertussis transmission to newborns through immunisation

Conditions: Pertussis

Summary: this study aims to establish an effective method to inform parents or close relatives of newborns about the risk of pertussis transmission to newborns and the advantages offered by the cocooning strategy (vaccinating those who are in close contact with the newborn) by assessing the factors that affect the parents' decision-making to accept pertussis immunisation.

two phases are foreseen in the study. the 'questionnaire design' phase will be conducted in order to finalise the electronic questionnaire. the enrollment phase will involve the administration of the final web-based questionnaires to the subjects included in the enrollment phase. the data generated in this study will be useful to inform parents of newborns about the advantages of vaccinating people who are in close contact with the newborn even before the baby is born in order to prevent the transmission of pertussis to the newborn. no vaccine will be administered during this study.

Eligibility criteria:
inclusion criteria: * subjects who the investigator believes that, can and will comply with the requirements of this protocol (ability to understand the study objectives and the questions asked, and ability to operate a computer). * written informed consent obtained from the subject. * subjects aged ≥ 18 years at the time of study start who are either: contacts of newborns (aged ≤ 6 months). or expecting mothers in their last trimester of pregnancy or their partners, who will be in close contact with the newborn. • subjects who will be eligible for pertussis booster vaccination and have not received any pertussis vaccination in the last 2 years (before study start). exclusion criteria: * subjects who have participated in the 'questionnaire design' phase (applicable only for subjects who will participate in the enrollment phase of the study). * subjects with a contraindication to pertussis vaccination. * subjects who declare to be in principle against vaccination. * subjects who declare to be in a chronic physical condition and not compatible with vaccination. * subjects with a history of pertussis in the last 5 years (before study start). * history of non-response to pertussis vaccination. * subjects with mental deficiency. * subjects with unstable chronic health condition(s).

Keywords: cocooning web-based questionnaire italy pertussis spain survey
enalapril after anthracycline cardiotoxicity

Conditions: Cardiovascular Diseases; Heart Diseases; Heart Failure; Myocardial Diseases

Summary: to determine if the chronic administration of enalapril, an inhibitor of angiotensin converting enzyme (ace), reduces progression of cardiac dysfunction in pediatric oncology patients who have received anthracyclines, and who are not currently on digoxin, diuretics, or vasodilators for heart failure.

background: pediatric oncology patients who have been treated with anthracycline therapy as a part of their chemotherapeutic regimen often subsequently develop left ventricular failure. the optimal medical management is not known. this trial will be the first to provide comprehensive data on a well characterized population regarding the role of afterload reduction using enalapril to treat ventricular dysfunction after anthracycline chemotherapy design narrative: randomized, double-blind. randomization was stratified by total anthracycline dose, follow-up time from treatment, and age at time of treatment. all patients received the following baseline tests: maximal cardiac index (mci) on cycle ergometry; echocardiogram/doppler determined left ventricular end systolic wall stress (esws); gated nuclear angiography (gna) to determine left ventricular ejection fraction; holter monitoring for 24 hour ecg monitoring. patients were randomized to either enalapril or placebo. follow-up visits were conducted to ensure compliance and screen for side effects. mci and esws were measured twice yearly, while all four tests were repeated at the conclusion of the trial, after four to five years of treatment. the primary outcome variables were the rate of decline in mci and the rate of increase in esws. secondary outcomes were the change in left ventricular ejection fraction and the incidence of arrhythmias. a second aim of the study was to develop an algorithm to determine indications for enalapril use if the study succeeded in showing a treatment effect. this required modeling the probability of cardiac dysfunction given patient characteristics at treatment, treatment type, cardiac status during treatment and at follow-up, and the development of cost effectiveness and medical decision making models testing the proposed algorithm. the study completion date listed in this record was obtained from the "completed date" entered in the query view report system (qvr).

Eligibility criteria:
boy and girl pediatric oncology patients, at least two years off treatment, with some cardiac dysfunction, but not congestive heart failure, after receiving anthracyclines. patients were not on digoxin, diuretics, or vasodilators for heart failure.
determining rates of cardiovascular complications among patients of a managed diabetes care program

Conditions: Disease Management; Diabetes Complications; Diabetic Vascular Complications; Diabetic Neuropathy; Diabetic Nephropathy; Diabetic Retinopathy

Summary: the primary objective of this study is to identify whether cardiovascular complication rates are lower in patients who participate in managed diabetes care, in comparison to provincial and national rates. this study will involve an electronic medical record (emr) chart audit, augmented by a manual review of hospital and other pertinent medical records, as necessary.

the decide study will identify whether cardiovascular complication rates (the composite rate of myocardial infarction (mi), percutaneous coronary intervention (pci), coronary artery bypass grafting (cabg), stroke, carotid endarterectomy, peripheral revascularization, and peripheral amputation) are lower in patients who participate in managed diabetes care by adec in comparison to provincial and national rates. comparison statistics will be provided by the institute of evaluative sciences (ices) atlas 2003 and other diabetes studies such as the 2005 dice study. complications such as nephropathy and retinopathy will be documented, along with hospitalization rates and all cause mortality. clinical outcomes relevant to diabetes management such as blood pressure and lipids will also be compared.

Eligibility criteria:
inclusion criteria: 1. ambulatory patients over the age of 18 years with diabetes mellitus. 2. current enrolment in adec program (\>6 months)or new enrolment in adec program (\<6 months). 3. confirmed diagnosis of diabetes mellitus, according to the current canadian diabetes guidelines. 4. informed consent provided exclusion criteria: 1. history of only gestational diabetes. 2. non-ghc member. 3. ghc patients with diabetes who do not attend the adec program. 4. unable to give informed consent. 5. any conditions/circumstances that prevent the patient from attending adec sessions or participating fully in the program. 6. refusal to allow research staff access to medical records, including hospital charts.

Keywords: amputation angina angiography angioplasty arterial disease artery disease bypass cabg cad carotid cerebral accident chf crf cva endarterectomy heart attack heart failure infarct kidney disease kidney failure laser nephropathy neuropathy pad pci percutaneous coronary percutaneous transluminal pvd renal failure retinopathy revascularization schemia stenosis stent stroke transient ulcer vascular disease
role of mitophagy in myeloid cells during coronary atherosclerosis.

Conditions: Coronary Atherosclerosis

Summary: atherosclerosis (deposition of a plaque essentially composed of lipids on the artery walls) is a frequent condition and is a leading cause of death worldwide. in addition to the long-established risk factors such as age, hypertension, diabetes or sedentary lifestyle, it has been demonstrated that immune cells can participate in the genesis of atherosclerotic plaques through metabolic and mitochondrial reprogramming. a non-invasive marker of this immune reprogramming has yet to be identified. through the comparison of a group of atheromatous patients and a group of non-atheromatous patients, this study aims to evaluate this reprogramming phenomenon using a novel non-invasive method. this monocentric interventional study will take place at the dijon bourgogne university hospital and will include 50 patients divided into 2 groups: "atheromatous coronary patients" and "non-atheromatous patients". the duration of participation in this study is 1 month. this study is based on usually performed procedures. only blood samples will be taken on a catheter usually used during any cardiac surgery in addition to the medical care that is provided during hospitalization.


Eligibility criteria:
inclusion criteria: - person who provides oral consent group 1: - patient scheduled for cardiac bypass surgery (isolated procedure) with extracorporeal circulation group 2: * patient scheduled for valve ou ascending aorta surgery with extracorporeal circulation * no coronary lesion * no peripheral arterial disease (limbs, carotids, aortic aneurysm) exclusion criteria: * person not affiliated with national health care system * medication that alters mitochondrial function (chloroquine, hydroxychloroquine, rapamycin, carbamazepine, resveratrol, sildenafil) * person under a legal protection measure (curatorship, guardianship, tutorship) * pregnant, parturient or breastfeeding women * major unable to express consent * minor
a study of mobility outcomes in post-pulmonary embolic disease

Conditions: Pulmonary Embolism

Summary: the purpose of this study is to develop a unique structure and delivery of home-based exercise through multidisciplinary expertise of cardiovascular medicine specialists and cardiac physiologists using an interactive care plan.


Eligibility criteria:
inclusion criteria: acute intermediate-risk pe, defined as: * intraluminal filling defect in segmental or larger vessels on computed tomography pulmonary angiography or high-probability ventilation/perfusion scan and * evidence of right ventricular enlargement by computed tomography (rv to lv ratio \>1) or echocardiography; and/or right ventricular dysfunction by transthoracic echocardiography. these imaging characteristics must be in the setting of acute pe rather than explained by a prior chronic condition. acute high-risk pe, defined as: * intraluminal filling defect in segmental or larger vessels on computed tomography pulmonary angiography or high-probability ventilation/perfusion scan and * evidence of right ventricular enlargement by computed tomography (rv to lv ratio \>1) or echocardiography; and/or right ventricular dysfunction by transthoracic echocardiography. these imaging characteristics must be in the setting of acute pe rather than explained by a prior chronic condition; and * hypotension (systolic blood pressure \< 90 mm hg sustained for more than 15 minutes; or requiring vasopressors) or cardiogenic shock due to acute pulmonary embolism. exclusion criteria: * inability to ambulate independently, which is necessary to perform 6mwd (may be self-reported or as deemed by physical therapy during inpatient evaluation). * if patient requires supplemental oxygen during ambulation, this does not exclude patient from participation and will be noted during ecrf. * prior history of pulmonary embolism * history of cteph or pulmonary arterial hypertension * unable to read a questionnaire in english * unable to return for baseline, 3- or 6-month follow-up visit * pregnancy-associated pulmonary embolism * life expectancy \<1 year based on comorbidities * unable/unwilling to provide informed written consent
skin fluorescent imaging (sfi) system in patients with nevi

Conditions: Nevus; Dysplasia; Epithelial

Summary: the sponsor has developed the skin fluorescent imaging (sfi) system, an in vivo imaging modality, for the purpose of providing physicians with insight into the biological changes occurring during tissue remodeling in a nevus.

the sfi system, a non-invasive point-of-care imaging system, is able to detect markers associated with tissue remodeling and thus provide real-time information about biological and structural changes occurring in nevi indicative of dysplastic transition.

Eligibility criteria:
inclusion criteria: in order to be eligible to participate in this study a subject must meet all of the following criteria: * provide a signed and dated informed consent form * age ≥ 18 years old * subjects must present with suspicious atypical nevi scheduled for a biopsy\* * nevi with at least 1 cm of skin surrounding the mole * nevi must be accessible to the sfi imaging device * excisional or a tangential excision with a dept of 1 to 2 mm biopsy will be performed for the mole tested within 21 days of testing. * nevi with clinically atypical features only 1 mole per eligible subject will be sfi tested in this study. \*note: a subset of patients (\~10%) with benign nevi (by clinical observation) who wish to have nevi removed for cosmetic reasons will be enrolled as negative controls. exclusion criteria: an individual who meets any of the following criteria will be excluded from participation in this study: * subjects who are younger than 18 years old * lesions that are consistent with - features of keratosis and keratin plugs * basal cell carcinoma * squamous cell carcinoma * challenging anatomical location (e.g., body cervices) * subjects with nevi that fit the inclusion criteria but are: * less than 1 cm from the eyes * on the palms of the hands or soles of the feet * associated with scar tissue * mucosal lesions * ulcerated lesions / breached skin * lesions with some clinical certainty of being melanomas (large, dark, etc.) * any nevi with ink marking including tattoos, on or adjacent to the nevi * lesions treated with local anesthesia such as lidocaine prior to enrollment * lesions larger than 20 mm or too large to allow imaging * subject is known to be pregnant * subject who is mentally or physically unable to comply with all aspects of the study * subject who is undergoing systemic cancer treatment within 6 months of sfi testing * subject with hypersensitivity to any of the sfi reagents * subjects with known sensitivity to fluorescent dyes * any subject who has previously participated (testing to biopsy) in sfi 003

Keywords: nevus atypical nevi mole skin imaging
tiotropium (18 mcg) once daily via the handihaler® in patients with chronic obstructive pulmonary disease (copd)

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: the primary objective of this trial is to determine whether treatment with tiotropium (18 mcg) capsule once daily via the handihaler reduces the proportion of patients with copd experiencing an exacerbation and the proportion of patients hospitalized for an exacerbation during a six month observation period.


Eligibility criteria:
intensity-modulated radiation therapy combined with cisplatin or nedaplatin chemotherapy in nasopharyngeal carcinoma

Conditions: Nasopharyngeal Carcinoma

Summary: this phase ii trial is studying cisplatin or nedaplatin combine with imrt to evaluate which one is better efficacy and security in nasopharyngeal carcinoma.


Eligibility criteria:
inclusion criteria: age≥18,t1-2an1-3;t2-4nxnpc,vegfr+,++,kps\>70,life expectancy≥6 months, no uncontrolled hypertension,cardiac failure,diabetes,lunacy exclusion criteria: distant metastasis, recurrent disease
pet-based evaluation of chemotherapy-induced brain damage in lymphoma

Conditions: Lymphoma

Summary: positron emission tomography (pet) with 18-fluoro-deoxy-glucose (pet-fdg) is emerging as a promising approach for detecting brain lesions in dementia, among which alzheimer's disease has been the most widely studied.

alteration of neuro-cognitive function induced by chemotherapy has been extensively documented in breast carcinoma patients. these modifications consist in the decrease of memory, intellectual capacity, speed analysis, and represent a real limitation for patients, sometimes durable. aggressive lymphomas (diffuse large b cell lymphomas/dlbcl) represent a common disease, the standard being rituximab-cyclophosphamide-doxorubicine-vincristine-prednisone (rchop) regiment which contains, as for breast cancer patients, anthracyclines. however, very little is known about the incidence and severity of cognitive function alteration in these patients. the occurrence of such complications should also be facilitated because of frail cognitive states due to age and co-morbidity. cognitive function alteration is usually measured by neuropsychological tests (npt) which are easy to handle and sensitive, but could lack specificity, in the context of general degradation which is often observed in hematological patients. positron emission tomography with 18-fluoro-deoxy-glucose (pet-fdg) is emerging as a promising approach for detecting brain lesions in dementia, among which alzheimer's disease has been the most widely studied. in our center, the investigators have already described glucidic hypometabolism in several brain territories associated with alzheimer's disease and other dementia. moreover, uptake quantification and topography are useful markers for determining the type of the disease and progression. pet-fdg received very little attention for the detection of chemotherapy-induced brain damages.

Eligibility criteria:
inclusion criteria: * histologically documented dlbcl * previously untreated * with international prognostic index (ipi) 0 or 1, or 2 without general state alteration (oms≤2) * submitted to rchop regimen (according to gela's standard protocol) * normal pre-treatment brain ct scan * able to give informed consent * speaking well french language * benefiting from general medical insurance * registered in the national listing of patients for biomedical research. exclusion criteria: * ipi \> or =3 * medical history of another cancer, or psychiatric or pre-dementia disorder, or convulsion * barbituric regular use which can't be stop * human immunodeficiency virus (hiv) patients * unstable diabetes mellitus * pregnancy

Keywords: positron-emission tomography chemotherapy-induced brain damage neuro-cognitive function alteration
food, activity and behavior study

Conditions: Obesity

Summary: the purpose of this research is to test the effects of the dietary and physical activity guidelines for americans on health and on eating and exercise behaviors.

the dietary guidelines for americans (dga), which include the physical activity guidelines for americans (paga), is the primary united states (u.s) government resource for weight control. the researchers propose that chronic, low grade inflammation (clgi) limits weight control by acting upon physiological and behavioral factors that moderate weight control. diet and exercise reduce clgi and provide weight control, but no one has investigated the efficacy of the dga and paga to reduce clgi, whether reduced clgi promotes greater weight control, and the moderating roles of physiological and behavioral factors on the association of reduced clgi with weight control. to accomplish this, the researchers will conduct a 6-month trial in 224 obese adults; a 3-month controlled feeding trial with four dietary arms; 1) dga with weight loss, 2) western diet with weight loss,3) dga diet weight maintenance, 4) western diet weight maintenance. each dietary arm will have paga-recommended exercise and non-exercise arms. post-trial is a 3-month weight maintenance period. the primary outcome is change in c-reactive protein (crp), a marker of clgi. the results will inform the dga and paga; thereby helping clinicians, public health workers, and policymakers to improve the health of americans.

Eligibility criteria:
inclusion criteria: * obese (bmi 30.0 kg/m2 - 350 lbs \[maximum weight for dual energy x-ray absorptiometry (dxa) machine\]) * no contraindications to participate in exercise * hs-crp level ≥3.0 and ≤10.0 mg/l or two consecutive measures of \>10.0 mg/l measured two weeks apart * access to high-speed internet exclusion criteria: * taking chronic anti-inflammatory medications * being pregnant, lactating, or planning to become pregnant * diagnosed eating disorder * taking weight loss medication * smoking * overt hypothyroidism * cancer * physical conditions that prevent safe exercise * liking of \<3 out of 10 for all available physical activity modes * currently exercising for more than 30 minutes per day \>3 days per week * unwilling to continue with current exercise routine * not willing to comply with all study requirements * blood pressure greater than 140/90
a study of prevalence of the i50l mutation when atv treated patients fail the regimen

Conditions: HIV Infections

Summary: the purpose of this study is to find out the frequency of the i50l substitution among patients experiencing treatment failure on an atazanavir-containing regimen.


Eligibility criteria:
inclusion criteria: * atazanavir - containing antiretroviral regimen * confirmed virologic failure defined as either: 1. hiv rna by pcr greater than or equal to 1000 copies/ml after achieving a value of \<400 copies/ml on at least 2 consecutive measurements or 2. hiv rna greater than or equal to 1000 copies/ml after 24 weeks of continuous therapy * at least 18 years old exclusion criteria: * unable to give informed consent * prisoners or subjects involuntarily incarcerated for treatment of psychiatric or physical illness

Keywords: hiv/aids treatment experienced
evaluation of the presence and effects of kinesiophobia in multiple sclerosis

Conditions: Multiple Sclerosis; Kinesiophobia

Summary: the aim of this study was to evaluate the presence of kinesiophobia in multiple sclerosis and to investigate the effect of kinesiophobia on physical activity, functional status, quality of life and depression.

90 people, including 45 patients and 45 healthy control groups, were included in the study. demographic data of all participants were recorded. tampa scale of kinesiophobia (tsk), beck depression inventory (bdi), quality of life scale short form-36 (sf-36), international physical activity questionnaire short form (ipaq-sf), functional ambulation classification (fas), in addition to multiple sclerosis group, functional independence measure (fim), expanded disability status scale (edss) were implemented.

Eligibility criteria:
inclusion criteria: * having a definitive diagnosis of ms according to the 2017 revised mcdonald diagnostic criteria * expanded disability status scale (edss) score between 0-6.5 * be between the ages of 18-65 * volunteering to participate in the study exclusion criteria: * having orthopedic, psychiatric and other chronic diseases other than ms that may affect physical and cognitive status * expanded disability status scale (edss) score \>6.5 * being in the ms attack period

Keywords: multiple sclerosis kinesiophobia fear of movement